SAGE Therapeutics (SAGE) Receives a New Rating from Oppenheimer

Oppenheimer analyst Jay Olson initiated coverage with a Buy rating on SAGE Therapeutics (NASDAQ: SAGE) today and set a price target of $170. The company’s shares opened today at $127.36.

Olson noted:

“We initiate coverage of SAGE with an Outperform rating and $170 PT, based on our view that SAGE should become a leader in anti-depressants with two drugs in late-stage development: IV brexanolone for Postpartum Depression (PPD) and oral SAGE-217 for PPD and Major Depressive Disorder (MDD). Three near-term catalysts could unlock significant value, especially for SAGE-217, a key contributor to our valuation. We view these catalysts as skewed toward positive outcomes: (1 and 2) brexanolone is well positioned for an upcoming and PDUFA (12/19), in our opinion, based on a favorable risk/benefit ratio in an indication with no FDA- approved therapy; and (3) Ph3 PPD data from the ongoing SAGE-217 trial in 4Q18.”

According to, Olson ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.8% and a 40.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on SAGE Therapeutics is a Strong Buy with an average price target of $219.67.

See today’s analyst top recommended stocks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $90 million and GAAP net loss of $16.98 million. In comparison, last year the company had a GAAP net loss of $73.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts